Literature DB >> 18022011

Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.

B Wysoczanska1, K Bogunia-Kubik, D Dlubek, E Jaskula, A Sok, D Drabczak-Skrzypek, M Sedzimirska, A Lange.   

Abstract

INTRODUCTION: Allotransplantation in chronic myeloid leukemia (CML) patients offers long-lasting remissions, which largely depend on immunologic surveillance of alloreactivity. Alloreactivity in CML patients has a durable potential. However a large proportion of relapsing patients, who have to undergo donor lymphocyte treatment is still abundant.
METHODS: We studied a group of 31 CML patients post allogeneic transplantation for their level of T-cell receptor excision circles (TREC) and proportion of naive and memory/effector T cells in the peripheral blood (PB). TREC numbers were determined by quantitative PCR (qPCR) and T-cell subsets CD4(+)CD27(+)CD45RO(-), CD4(+)CD27(-)CD24RO(+), CD4(+)CCR7(+), and CD4(+)CCR7(-) by flow cytometry. Patients were analyzed for posttransplant chimerism, type of bcr-abl transcripts, and number of TREC in association with the presence of chronic graft-versus-host disease (cGVHD) and relapse. CML patients with TREC+ in PB had a higher proportion of CD4(+)CD27(+)CD45RO(-) cells (3.54 vs 2.45%; P = .105) and CD4(+)CCR7(+) cells (4.85 vs 2.67%; P = .007), and a lower proportion of CD4(+)CD27(-)CD45RO(+) cells (5.55 vs 9.09%; P = .037). The incidence of cGvHD was reduced among TREC+ CML patients (3/14 vs 11/17; P = .006).
RESULTS: The 5 out of 31 CML patients who relapsed were characterized by the presence of b2a2, b3/a2 or both type of transcripts, a lack of TREC in the blood, and a lower proportion of naïve and effector/memory T cells. No association was observed between any of HLA specificities, type of bcr-abl transcripts and incidence of relapse.
CONCLUSION: The presence of TREC is affected by chronic GvHD; TREC negativity may constitute a risk of mixed chimerism and relapse.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022011     DOI: 10.1016/j.transproceed.2007.08.036

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Twisting immune responses for allogeneic stem cell therapy.

Authors:  Shengwen Calvin Li; Jiang F Zhong
Journal:  World J Stem Cells       Date:  2009-12-31       Impact factor: 5.326

2.  Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.

Authors:  Wei Liu; Han-Yun Ren; Yu-Jun Dong; Li-Hong Wang; Yue Yin; Yuan Li; Zhi-Xiang Qiu; Xi-Nan Cen; Yong-Jin Shi
Journal:  Int J Hematol       Date:  2012-11-23       Impact factor: 2.490

Review 3.  T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome.

Authors:  Ahmed Gaballa; Mikael Sundin; Arwen Stikvoort; Muhamed Abumaree; Mehmet Uzunel; Darius Sairafi; Michael Uhlin
Journal:  Int J Mol Sci       Date:  2016-10-11       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.